🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Colgate-Palmolive stock target raised, holds rating on growth outlook

EditorNatashya Angelica
Published 07/22/2024, 11:31 AM
CL
-

On Monday, Colgate-Palmolive Company (NYSE:CL) saw its stock price target increased by Stifel from $95.00 to $105.00, while the firm maintained a Buy rating on the stock. This adjustment comes as the company is expected to exhibit superior organic sales and volume growth, coupled with gross margin expansion in the coming quarters.

The analyst from Stifel bases the new price target on an 18 times multiple of the estimated 2025 EBITDA. The rationale behind the modest premium over competitors such as Procter & Gamble is Colgate-Palmolive's anticipated outperformance in organic sales and volume.

This forecast is supported by accelerating volume trends and significant pricing contributions, especially from high inflation markets like Argentina and in the pet nutrition segment where input costs remain high.

Colgate-Palmolive's ability to implement price increases amidst economic uncertainties is attributed to its substantial market share in crucial categories, notably oral care, which accounts for approximately 43% of its sales. The company's oral care segment has been performing particularly well, with toothpaste market share increasing for eight consecutive quarters after a period of underperformance.

The analyst also projects a strong input from the pet nutrition division. This optimism includes an expected reduction in the impact from the company's decision to exit the private label business, which is anticipated to contribute positively to Colgate-Palmolive's financial performance.

In other recent news, Colgate-Palmolive has been the subject of several significant developments. The company's Q1 2024 results showed a robust 6% net sales growth and a substantial improvement in gross margins. Deutsche Bank has maintained a Buy rating on the company's stock, raising the price target to $104, based on expectations of an upward risk to the company's full-year earnings and organic sales growth forecasts.

Morgan Stanley also raised its stock price target for Colgate-Palmolive to $103, indicating confidence in the company's ability to sustain high operational and earnings growth. Argus increased its price target to $107, maintaining a Buy rating due to the company's consistent organic sales growth and commitment to product innovation.

In other company news, Jeff Duncan, representative of South Carolina's 3rd congressional district, sold stocks in Colgate-Palmolive from his Raymond James IRA, reflecting a shift from individual stocks to a more diversified retirement savings plan. These recent developments underscore the active interest and ongoing changes in Colgate-Palmolive's market performance and strategic positioning.

InvestingPro Insights

Following the recent price target increase by Stifel, Colgate-Palmolive Company (NYSE:CL) continues to show promising financial metrics and analyst confidence. With a robust market capitalization of $79.97 billion, Colgate-Palmolive stands as a significant player in the consumer goods sector.

The company's price-to-earnings (P/E) ratio, which is a key indicator of its valuation, is reported at 30.83, reflecting a slight adjustment to 30.02 when considering the last twelve months as of Q1 2024. This valuation is complemented by a PEG ratio of 0.48 for the same period, suggesting potential for growth relative to earnings.

Investors may also find the company's gross profit margin of 59.0% particularly impressive, indicating strong operational efficiency and cost management. Colgate-Palmolive's stock is trading near its 52-week high, at 98.11% of the peak value, highlighting the positive market sentiment surrounding the stock.

InvestingPro Tips further enrich our understanding of Colgate-Palmolive's financial health and investment potential. The company has not only raised its dividend for 34 consecutive years but also maintains a reputation for low price volatility, which could be appealing for investors seeking stability.

Moreover, with 5 analysts having revised their earnings upwards for the upcoming period, there is an optimistic outlook for the company's financial future. For those interested in deeper analysis and additional insights, InvestingPro offers more tips on Colgate-Palmolive, and users can take advantage of the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.